“We see concern surrounding ValRox’s regulatory and market prospects as overblown and we’re increasingly confident that a potential launch could meet/beat what we see as relatively low expectations,” MacKay wrote in a note published Friday.MacKay notes that Kuvan, another BioMarin drug that treats phenylketonuria and is one of the company’s top sellers, will begin to face generic competition at the end of this year.